PGEN (Precigen) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PGEN Precigen Inc PGEN
49 GF Score
Price $6.09
GF Value $15.17
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Precigen Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PGEN
49GF Score
Precigen Inc PGEN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precigen (PGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of $6.09 is trading 59.9% below its estimated GF Value™ of $15.17. GuruFocus considers Precigen to be Possible Value Trap.

Key valuation signals for PGEN:

  • Short Ratio:
  • GF Value™: $15.17 vs. price of $6.09 (59.9% below fair value)
  • GF Score™: 49/100 with 8 warning signs

No single metric tells the full story. See the PGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges I5X:Germany
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
49GF Score

Get the complete analysis for PGEN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.09
Price
$15.17
GF Value